PharmaDepth

Company profile

MADRIGAL PHARMACEUTICALS, INC.

NASDAQ:MDGLBiotechnology: Pharmaceutical Preparations

Drug pipeline (1)

AssetStageRevenueTrialsStatus
REZDIFFRAapproved$364.3MQ2 202619approved

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (20)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT04197479phase3completed2019-12-162023-01-06Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients
NCT04951219phase3active_not_recruiting2021-07-092027-03-01Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
NCT05500222phase3active_not_recruiting2022-08-262026-12-01Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
NCT03900429phase3active_not_recruiting2019-03-282028-01-01Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
NCT06397872phase1completed2024-03-062024-09-16Madrigal Pharmaceuticals, Inc.A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function

FDA applications (1)

ApplicationApprovedTypeApplicantProducts
NDA 2177852024-03-14NDAMADRIGAL PHARMACEUTICALS INC